Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
Disodium pamidronate (APD) is a potent inhibitor of bone resorption, with less risk of defective mineralization than earlier bisphosphonates. We assessed the response to six spaced low-dose intravenous infusions of APD given at intervals of approximately 6 weeks followed by weekly infusions if bone turnover remained abnormal. Three groups of 10 patients were studied, each group receiving infusions of 15, 30, or 45 mg. Hydroxyproline excretion fell by 62% and alkaline phosphatase was reduced by 72%, with no difference between the dose levels. A total of 21 patients (70%) achieved normal levels of bone turnover, indicating that low-dose infusions of APD are a safe and effective treatment for Paget's disease.
Stone
M D
MD
University Hospital, Nottingham, England.
Hawthorne
A B
AB
Kerr
D
D
Webster
G
G
Hosking
D J
DJ
D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007262:Infusions, Intravenous; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000378:metabolism; D000077268:Pamidronate; D010710:Phosphates / Q000097:blood
D004164:Diphosphonates; D010710:Phosphates; D000469:Alkaline Phosphatase; D000077268:Pamidronate; D006909:Hydroxyproline; D002118:Calcium